Additionally, primary IDH1 R132-mutated purified AML blasts showed a 1.5–2.0-fold increase in ACACA gene expression compared to CD34+ hematopoietic stem and progenitor cells (Supplementary Fig. 4c,d) and were selectively sensitive to TOFA treatment compared to IDH1 wild-type AML blasts (IC50 1.1 versus 6 μM, P value=0.01, Mann–Whitney) (Fig. 3e). This evidence concerns the gene IDH1 and acute myeloid leukemia.